Advertisement
01/20/2022

FDA green-lights Alembic’s generic Comtan

Entacapone tablets have a market value of roughly $10.5 million for the 12 months ending September 2021.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Alembic has received the Food and Drug Administration’s permission for entacapone tablets in a dosage strength of 200 mg.

The product is the generic of Orion’s Comtan.

[Read more: Alembic obtains FDA nod for 2 generics]

The drug is indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with Parkinson's disease.

Entacapone tablets, 200 mg have a market value of roughly $10.5 million for the 12 months ending September 2021, according to IQVIA.

Read more: Alembic debuts generic Zebeta]

    Advertisement
    Advertisement